RecruitingNCT07663357
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
Sponsor
Beneficência Portuguesa de São Paulo
Enrollment
1,000 participants
Start Date
May 11, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with cardiotoxicity. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07663357
Related Trials
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
NCT07588425
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT07761910
The CARDIOPROTECT Trial
NCT076544261 location
The STOP-MED CTRCD Trial
NCT0618343714 locations
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
NCT066990568 locations